Half Year 2025 Investor Presentation

• 36% increase in revenue during H1 2025
• 7% increase in recurring revenue
• Launched Ovie, a Gen AI-powered Care Assistant

Oneview Healthcare Plc reported its H1 2025 financial results, highlighting a 36% increase in revenue to €6.3 million and a 7% growth in recurring revenue to €3.8 million. The company's gross margin was 61%, down from 73% in H1 2024, due to a greater proportion of deployment revenue. Oneview's operating EBITDA loss was €4.5 million, impacted by restructuring charges and previous investments to support expected deployment activity. The company had €8.2 million in cash as of June 30, 2025, and executed a restructuring in June that reduced global headcount by around 10% and is expected to deliver annual cost savings of €1.1 million. Oneview added two new customer logos during H1 2025 and secured a three-year contract extension with a key strategic customer, driving over 20% year-on-year growth in annual recurring revenue from this customer. The company also launched its first initiative from its AI strategy, Ovie, a Gen AI-powered Care Assistant, and became one of the first companies on the ASX and in the connected care sector to achieve ISO 42001 certification for its AI Management System.

Oneview has a record US sales opportunity pipeline comprised of potential direct sales and sales under the Baxter VAR partnership, with several additional logos in contract negotiation. The company will deliver a new user experience in H2 2025 and continue developing AI-powered products. Oneview is also progressing towards more efficient deployments and expects early efficiency gains from the adoption of AI-powered tools across the business.